Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Elucid raises $80-million in Series C round

Closely-held Elucid raised $80-million to drive the commercialization of its AI-powered cardiovascular diagnostic tools. The round was led by Elevage Medical Technologies. Elucid’s FDA-cleared software is a non-invasive...

November 9, 2023

Markets

AGP ups Myomo to buy; PT $4.60 from $2

Alliance Global Partners upgraded Myomo (NYSE:MYO) to “buy” and raised its price target to $4.60 from $2. The stock was quoted at $1.85 midday on Nov.8. Myomo develops and markets the MyoPro product line of lightweight...

November 8, 2023

Developments

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical (NASDAQ:PROF; TSX:PRN) reported that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded TULSA’s HCPCS C code, C9734, for use in the ambulatory surgical center (ASC) setting...

November 3, 2023

Developments

iBio adds ShieldTx to tech stack, enhances immune-oncology pipeline

iBio (NYSEA:IBIO) launched ShieldTx, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. The addition of...

November 3, 2023

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

Hepion Pharmaceuticals (NASDAQ:HEPA) published a new research study in mice where rencofilstat prevented the growth of human hepatitis C virus (“HCV”)-associated liver tumors. HCV-infected mice developed small liver...

October 25, 2023

Developments

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

PharmaJet launched a study in Nigeria to evaluate the intradermal administration of a fractional inactivated poliovirus vaccine (fIPV) using the company’s Tropis ID Needle-free Injection System. Children at 22 urban and...

October 25, 2023

Executive Moves

SAB Biotherapeutics names Michael G. King Jr. as CFO

SAB Biotherapeutics (NASDAQ:SABS) appointed Michael G. King Jr. as CFO, effective Oct 30. Mr. King replaces Russell Beyer, who is expected to step down on Nov. 15 and remain a senior advisor with the company for the...

October 25, 2023

Markets

Cantor starts Adlai Nortye at OW; PT $30

Cantor Fitzgerald launched coverage of Adlai Nortye (NASDAQ:ANL) with an “overweight” rating and price target of $30. The stock closed at $8.52 on Oct 24. The company is focused on the discovery and development of...

October 25, 2023

Developments

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Personalis (NASDAQ:PSNL) presented positive data on its NeXT Personal platform’s ability to detect and monitor residual and recurrent disease (MRD) in patients with early-stage lung cancer. NeXT Personal is a whole...

October 23, 2023

Developments

Anixa Biosciences appoints Dr. Mark Goldberg to Cancer Business Advisory Board

Anixa Biosciences (NASDAQ:ANIX) appointed Dr. Mark Goldberg as the ninth independent member of the company’s Cancer Business Advisory Board (CBAB). “Mark brings valuable clinical expertise in oncology, and his extensive...

October 23, 2023

Markets

JMP starts Vigil Neuroscience at MO; PT $23

JMP Securities initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “market outperform” rating and price target of $23. The stock was quoted at $6.50 midday on Oct 18. Vigil is developing novel therapies for...

October 18, 2023

Developments

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO technology was featured as a medical breakthrough in an Oct. 13 AARP article. The article introduces 57-year-old Tommy Saul, who was diagnosed with prostate cancer in...

October 13, 2023

Elucid raises $80-million in Series C round

AGP ups Myomo to buy; PT $4.60 from $2

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

iBio adds ShieldTx to tech stack, enhances immune-oncology pipeline

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

SAB Biotherapeutics names Michael G. King Jr. as CFO

Cantor starts Adlai Nortye at OW; PT $30

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Anixa Biosciences appoints Dr. Mark Goldberg to Cancer Business Advisory Board

JMP starts Vigil Neuroscience at MO; PT $23

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

General

More